Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling

PURPOSE: To overcome cytochrome P450 2D6 (CYP2D6) mediated tamoxifen resistance in postmenopausal early breast cancer, CYP2D6 phenotype-adjusted tamoxifen dosing in patients with impaired CYP2D6 metabolism and/or the application of endoxifen, the most potent tamoxifen metabolite, are alternative tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickschen, Kristin, Eissing, Thomas, Mürdter, Thomas, Schwab, Matthias, Willmann, Stefan, Hempel, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058004/
https://www.ncbi.nlm.nih.gov/pubmed/24936398
http://dx.doi.org/10.1186/2193-1801-3-285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058004/
https://www.ncbi.nlm.nih.gov/pubmed/24936398
http://dx.doi.org/10.1186/2193-1801-3-285

Ejemplares similares